real-time news and commentary for investors
Wednesday, Nov 21
2012, 4:26 PM
Sanofi (SNY) subsidiary Genzyme announces that the Australian Therapeutic Goods Administration...
Sanofi (SNY) subsidiary Genzyme announces that the Australian Therapeutic Goods Administration has approved Aubagio, a treatment for patients with relapsing forms of multiple sclerosis. The approval will enable health professionals to prescribe the drug down under, making Australia the second country to gain marketing authorization for the treatment following FDA approval in September.